# Study of GRN163L With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non Small Cell Lung Cancer

> **NCT00510445** · PHASE1 · COMPLETED · sponsor: **Geron Corporation** · enrollment: 27 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Imetelstat Sodium (GRN163L)

## Key facts

- **NCT ID:** NCT00510445
- **Lead sponsor:** Geron Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2011-04
- **Final completion:** 2011-04
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2015-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00510445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00510445, "Study of GRN163L With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00510445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*